Prima BioMed (PBMD) Says IMP321 Combo Safe, Well Tolerated at 5mg Level in Breast Cancer
Tweet Send to a Friend
Prima BioMed Ltd (Nasdaq: PBMD) announces initial safety data from the first cohort of patients in its Phase IIb AIPAC ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE